Home › Mantle Cell Lymphoma › New York › New York City
Mantle Cell Lymphoma clinical trials in New York City, NY
12 studies for Mantle Cell Lymphoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Weill Cornell Medical Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
- Research Site, New York
- Research Site, New York
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
- Research Site, New York
A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
- NYU Langone, New York
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center - Bergen, New York
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Weill Cornell, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
Mantle Cell Lymphoma trials in other cities
- Houston, TX15 studies
- Baldwin Park, CA15 studies
- Durham, NC13 studies
- Seattle, WA12 studies
- Milwaukee, WI12 studies
- Boston, MA11 studies
- Nashville, TN11 studies
- Columbus, OH11 studies
- Chicago, IL10 studies
- Rochester, MN9 studies
- Portland, OR9 studies
- St. Louis, MO8 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.